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Functionally active gamma interferon (IFN-g) receptors consist of an a subunit required for ligand binding
and signal transduction and a b subunit required primarily for signaling. Although the receptor a chain has
been well characterized, little is known about the specific role of the receptor b chain in IFN-g signaling.
Expression of the wild-type human IFN-g receptor b chain in murine L cells that stably express the human
IFN-g receptor a chain (L.hgR) produced a murine cell line (L.hgR.mycb) that responded to human IFN-g.
Mutagenesis of the receptor b-chain intracellular domain revealed that only two closely spaced, membrane-
proximal sequences (P263PSIP267 and I270EEYL274) are required for function. Coprecipitation studies showed
that these sequences are necessary for the specific and constitutive association of the receptor b chain with the
JAK-2 tyrosine kinase. These experiments also revealed that the IFN-g receptor a and b chains are not
preassociated on the surface of unstimulated cells but rather are induced to associate in an IFN-g-dependent
fashion. A chimeric protein in which the intracellular domain of the b chain was replaced by JAK-2 comple-
mented human IFN-g signaling and biologic responsiveness in L.hgR. In contrast, a c-src-containing b-chain
chimera did not. These results indicate that the sole obligate role of the IFN-g receptor b chain in signaling
is to recruit JAK-2 into the ligand-assembled receptor complex.
Gamma interferon (IFN-g) is a cytokine produced by T cells
and natural killer cells that plays important roles in promoting
host defense and immunopathologic processes (9). IFN-g me-
diates its pleiotropic effects on cells by binding, in a strictly
species-specific manner, to a high-affinity receptor expressed
on the surface of nearly all cells (9). Functionally active IFN-g
receptors consist of two subunits: a 90-kDa a subunit, required
for ligand binding, ligand trafficking, and signal transduction,
and a b subunit (also known as accessory factor-1 or AF-1) that
must be species matched to the extracellular domain of the a
chain and which plays a critical role in signaling (9, 14, 29).
During the past few years, a great deal has been learned
about IFN-g-dependent signal transduction. This process is
known to require three intracellular proteins that belong to the
JAK-STAT signaling pathway. Two of these proteins are the
tyrosine kinases JAK-1 and JAK-2, which are activated upon
ligation of the IFN-g receptor and promote the phosphoryla-
tion and activation by dimerization of the third component,
which is the latent cytosolic transcription factor Stat1 (20, 26,
27, 33). Stat1 homodimers then translocate to the nucleus and
promote the transcriptional activation of IFN-g-inducible
genes (28). The recent demonstration that Stat1-deficient mice
are unable to mount responses to IFN-g (and IFN-a) either in
vitro or in vivo documents that this transcription factor and the
JAK-STAT pathway play obligate roles in mediating all IFN-
dependent biologic responses (5, 18).
Previous structure-function analyses of the IFN-g receptor
a-chain intracellular domain revealed two functionally im-
portant sequences that interacted with the IFN-g signaling
components. The first is a membrane-proximal L266PKS269
sequence required for the constitutive association of the a
subunit with JAK-1 (8, 11, 15). The second is a membrane-
distal Y440DKPH444 sequence that is a phosphorylation site for
IFN-g-inducible tyrosine kinase activity. When phosphory-
lated, this sequence forms the docking site on the receptor for
Stat1 (7, 11, 12). Thus, the ligand-dependent tyrosine phos-
phorylation of the IFN-g receptor a chain links receptor liga-
tion to signal transduction.
Whereas these studies elucidated the roles of the receptor a
subunit, JAK-1, and Stat1 in IFN-g signaling, they did not
provide insights into the functions performed by either the
receptor b subunit or JAK-2. Recently two studies have sug-
gested that the IFN-g receptor b chain interacts with JAK-2
(16, 22). However, neither study defined the b-chain sequences
responsible for mediating the interactions or elucidated the
molecular basis for ligand-induced receptor activation. To ad-
dress these issues, we performed a detailed structure-function
analysis of the human IFN-g receptor b-chain intracellular
domain. Our results confirm the observation that JAK-2 con-
stitutively associates with the receptor b chain and extend it by
defining the site on the receptor b chain required for JAK-2
binding. Moreover, by analyzing the functional activity of a
chimeric b-chain–JAK-2 protein, we show that the only role
played by the receptor b-chain intracellular domain in medi-
ating IFN-g-dependent induction of at least two distinct bio-
logic responses is to bring JAK-2 into the activated receptor
complex. Finally, we show that IFN-g induces the association
of its receptor subunits in intact cells and thereby document
that IFN-g signaling is the result of ligand-dependent assembly
and activation of the IFN-g receptor.
MATERIALS AND METHODS
Cells. Murine L929 cells stably transfected with the human IFN-g receptor
a-chain cDNA (L.hgR) were generated and cultured as described previously (7).
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L.hgR.mycb cell lines were generated by stable cotransfection of L.hgR with a
plasmid encoding either wild-type or mutant forms of the human IFN-g receptor
b chain (tagged at the N terminus with a 13-amino-acid peptide derived from
c-myc) and the plasmid pMON1118, which confers hygromycin resistance (3, 17).
L.hgR.mycb cells were selected in a solution containing Dulbecco modified
Eagle medium, 0.5 mg of G418 (Gibco BRL, Gaithersburg, Md.) per ml, and 0.5
mg of hygromycin B (Calbiochem, San Diego, Calif.) per ml as described pre-
viously (7).
Reagents. Purified recombinant human and murine IFN-gs were generously
provided by Genentech, Inc. (South San Francisco, Calif.). The antiphosphoty-
rosine monoclonal antibody (MAb) 4G10 was a kind gift of Brian Drucker
(Oregon Health Science University, Portland, Oreg.). Polyclonal JAK-2 anti-
serum was obtained from Santa Cruz Biotechnology (Santa Cruz, Calif.). Stat1-
specific antiserum was a kind gift of Chris Schindler (Columbia University, New
York, N.Y.). Brij-96 was purchased from Sigma Chemical Co. (St. Louis, Mo.).
All antibodies were biotinylated as described previously (3).
Epitope tag. A 13-amino-acid peptide tag, derived from the human c-myc
protein (SMEQKLISEEDLN) and recognized by the murine MAb 9E10 (im-
munoglobulin G1 isotype) (6), was engineered by PCR into the human IFN-g
receptor b-chain cDNA as described previously (4). The resulting recombinant
protein expressed the peptide tag 9 amino acids from the predicted N terminus
of the mature b chain. The myc-tagged b-chain cDNA (1,167 bp) was ligated into
the pSRa expression vector to generate the expression plasmid pSRa-mycb.
Site-directed PCR mutagenesis. Double-stranded DNA oligonucleotides were
synthesized on an Oligo 1000 DNA Synthesizer (Beckman, Fullerton, Calif.).
Internal mutations within the b-chain intracellular domain were engineered by
two-step PCR site-directed mutagenesis protocols using as a template a Blue-
script plasmid containing the mycb insert (BSKSmycb) according to a protocol
described previously (7). Chimeric b molecules that contained the myc-tagged
human IFN-g receptor b-chain extracellular and transmembrane domains fused
to full-length murine JAK-2 or murine c-src were generated by a protocol
described previously (31). All constructs were ligated into the pSRa vector. The
accuracy of all PCR-generated DNA was confirmed by automated sequencing
(Perkin-Elmer Corp., Foster City, Calif.).
DNA transfection. L.hgR cells were transfected by the calcium phosphate
precipitation method as described previously (7).
MHC class I enhancement assay. The ability of IFN-g to enhance major
histocompatibility complex (MHC) class I expression on wild-type or transfected
murine fibroblasts was examined by stimulating the cells for 72 h with 1,000
international reference units (IRU) of IFN-g per ml and staining them with an
H-2k-specific MAb as described previously (7).
Nitric oxide induction. L.hgR cells (6 3 104 per well) transfected with human
IFN-g receptor b-chain constructs were stimulated in triplicate with either lipo-
polysaccharide (LPS; 40 mg/ml) alone or a combination of LPS and 1,000 IRU of
human or murine IFN-g per ml. After 48 h of culture at 378C, supernatants were
harvested and the level of nitrite was determined as previously described (7).
Generation of MAbs. A panel of hamster MAbs specific for the human IFN-g
receptor b chain was generated according to a previously published protocol
(25) after immunization of Armenian hamsters with purified soluble extracellu-
lar domains of the human IFN-g receptor b chain prepared as described previ-
ously (1, 17). One of these antibodies, 2HUB-159, was used in our studies. All
MAbs used in this study were purified from spent culture supernatants by pro-
tein A affinity chromatography using the monoclonal antibody purification sys-
tem (MAPS) system as described previously (4).
Immunoprecipitation and Western blotting (immunoblotting). Cellular pro-
teins were immunoprecipitated with 2 mg of MAb specific for either the myc
epitope tag (9E10), the human IFN-g receptor a chain (GIR-94) (23), or the
human IFN-g receptor b chain (2HUB-159) in buffers containing 1% Triton
X-100 as described previously (11). Protein A precipitates were analyzed by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using 6
or 9% polyacrylamide gels under reducing conditions for the a and b chains,
respectively. Western blotting was conducted as described previously (11), and
blots were developed with the ECL Western blotting system.
Coprecipitations. L.hgR or L.hgR.mycb cells were harvested, resuspended to
7.5 3 107 cells per ml in phosphate-buffered saline (PBS) containing 10% fetal
calf serum, and treated with either PBS or 10,000 IRU of human IFN-g for 5 min
at 378C. The reaction was stopped by adding 10 ml of ice-cold PBS. Cells were
pelleted, and 7.5 3 107 cells were resuspended in 1.5 ml of Brij-lysis buffer (30)
(50 mM Tris [pH 7.5] containing 1% Brij-96, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA [ethylene glycol-bis(b-aminoethyl ether)-N,N,N9,N9-tetraacetic acid], 1
mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 5 mM iodoac-
etamide, 10 mM NaF, and 10 mg each of leupeptin and aprotinin per ml) and
incubated on a rotary wheel for 20 min at 48C. Cellular debris was pelleted by
centrifugation at 12,000 3 g for 10 min. The supernatants were precleared by
treatment with 40 ml of a 1:1 slurry of protein A-Sepharose for 30 min on a rotary
wheel at 48C followed by centrifugation at 12,000 3 g for 1 min. Cleared
supernatants were then incubated with 5 mg of either GIR-94, 2HUB-159, or
TR75-54.7 (a hamster MAb specific for the murine p75 tumor necrosis factor
[TNF] receptor [24]) for 45 min at 48C. Protein A-Sepharose was added to the
reaction mixture, and the incubation was continued for an additional 45 min. The
beads were collected by centrifugation at 8,500 3 g for 1 min at 48C and washed
four times with 1 ml of lysis buffer and once with 1 ml of PBS. Supernatants were
cleared again with protein A-Sepharose and were used for precipitation of JAK-2
as described above. In both cases, pelleted Sepharose beads were then resus-
pended in 30 ml of 23 Laemmli buffer containing 180 mM b-mercaptoethanol
and heated at 708C for 5 min and the supernatant was subjected to SDS-PAGE
and Western blot analysis.
Electrophoretic mobility shift assays. L.hgR cells (5 3 106) were resuspended
in 200 ml of PBS containing 10% fetal calf serum and treated with either PBS or
1,000 IRU of either human or murine IFN-g per ml for 20 min at 378C. The
reaction was stopped by addition of 1 ml of ice-cold PBS to each tube. Nuclear
extracts of the cells were prepared and assayed by electrophoretic mobility shift
analysis that employed a 32P-labeled oligonucleotide probe containing the IFN-
g-responsive element (GRR) derived from the promoter of the FcgRI gene
according to a previously described procedure (11).
RESULTS
Characterization of the mature human IFN-g receptor
b-chain polypeptide. At the beginning of this study, MAb re-
agents specific for the human IFN-g receptor b chain were not
available and the molecular mass of the mature polypeptide
was unknown. We therefore generated a panel of hamster
MAbs specific for the human IFN-g receptor b chain. To
characterize these antibodies, a recombinant form of the hu-
man b chain that contained a myc peptide epitope tag at the
amino terminus and was stably expressed in murine L929 cells
that also expressed the human IFN-g receptor a chain (L.hgR)
to produce the L.hgR.mycb cell line was generated. The
myc-tagged human b chain was immunoprecipitated from
L.hgR.mycb cells by using MAbs specific for either the myc
peptide tag (9E10) or the human receptor b chain (2HUB-
159). Immunoprecipitates were then analyzed by Western blot-
ting using biotinylated forms of each antibody (Fig. 1). In both
cases, a doublet that displayed molecular masses of 61 and 67
kDa was observed (Fig. 1, lanes 2, 4, 6, and 8). This pattern was
similar to the diffuse pattern that we obtained previously for
the murine homolog by using murine receptor b-chain-specific
MAbs (2). These results establish the apparent molecular mass
of the mature human IFN-g receptor b chain and document
the specificity of the b-chain MAb.
FIG. 1. Determination of the molecular mass of the human IFN-g receptor
b chain. L.hgR or L.hgR.mycb cells were lysed in buffers containing 1% Triton
X-100, and b chains were immunoprecipitated with the 9E10 MAb specific for
the myc tag (labeled myc) or the 2HUB-159 MAb specific for the human b-chain
extracellular domain (labeled Hub). The precipitates were subjected to SDS-
PAGE on 9% polyacrylamide gels and analyzed by Western blotting us-
ing biotinylated forms of either 9E10 (left panel) or 2HUB-159 (right panel).
Lanes 1 to 4 represent b-chain immunoprecipitates derived from 1.5 3 107
cells, lanes 5 and 6 represent those derived from 5 3 106 cells, and lanes 7
and 8 represent those derived from 1 3 106 cells. The species in lanes 5 and 6
running at approximately 55 kDa, indicated by the arrow and labeled NS, is
nonspecific and can be seen in lanes 7 and 8 with longer exposures. IP, immu-
noprecipitation.
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Localization of the functionally important IFN-g receptor
b-chain sequences to the membrane-proximal half of the in-
tracellular domain. To confirm that the epitope-tagged human
IFN-g receptor b chain was functionally active, we treated
either L.hgR or L.hgR.mycb cells with human IFN-g and mon-
itored, as a representative IFN-g response, expression of MHC
class I proteins. As shown previously (7), human IFN-g did not
enhance MHC class I expression on L.hgR cells (data not
shown). In contrast, human IFN-g upregulated MHC class I
expression on L.hgR.mycb cells (Fig. 2e). Thus, the presence
of the epitope tag on the N terminus of the human b chain did
not interfere with the function of this subunit in IFN-g signal-
ing.
This system allowed us to determine whether the intracellu-
lar domain of the human IFN-g receptor b chain is required in
the signaling process. To address this question, we stably ex-
pressed in L.hgR cells a truncation mutant (mycbDIC) that
lacked all but the first three amino acids of the 66-residue
cytoplasmic domain (Fig. 2b). L.hgR.mycbDIC cells failed to
respond to human IFN-g but remained responsive to murine
IFN-g (Fig. 2f and j). In contrast, a b-chain truncation mutant
lacking the 34 C-terminal residues (mycbD283-316) was capa-
ble of complementing human IFN-g responsiveness in L.hgR
cells (Fig. 2c and g). Mutation of all three intracellular-domain
b-chain tyrosines did not abrogate b-chain functional activity,
as evidenced by enhanced MHC class I expression in L.hgR
cells expressing the mycb3DY protein (Fig. 2d and h). Several
of these cell lines were also tested for the capacity to induce the
inducible nitric oxide synthase (iNOS) gene when exposed to
the combination of human IFN-g and LPS. In all cases, iNOS
induction corresponded with MHC class I enhancement (data
not shown). Thus, the membrane-proximal half of the IFN-g
receptor b-chain intracellular domain is sufficient for signaling
and intracellular-domain tyrosines are not required for func-
tion.
Identification of the functionally important residues within
the IFN-g receptor b-chain intracellular domain. To deter-
mine which residues within the first 32 cytoplasmic amino acids
of the b chain were functionally important, an alanine scan
mutagenesis in which blocks of four to seven contiguous amino
acids within this region were mutated to alanine was per-
formed (Fig. 3). Mutant b chains were then stably expressed in
L.hgR cells, and clonal transfected cell lines were tested for
responsiveness to human IFN-g. This analysis revealed that
only two closely spaced cytoplasmic domain sequences were
required for function: P263PSIP267 and I270EEYL274 (Fig. 3).
We considered the possibility that the lack of functional activ-
ity of these two b-chain mutants might be due to postsynthetic
truncation of the polypeptides. However, this possibility was
ruled out by showing that the nonfunctional mutant b chains
expressed in L.hgR.mycb263/7A and L.hgR.mycb270/4A cells
displayed the appropriate molecular masses as determined by
immunoprecipitation-Western blot analysis (Fig. 4B). A more
detailed mutagenesis analysis failed to identify a more re-
stricted functional core. Moreover, no single alanine substitu-
tion that abrogated b-chain function was found. The analysis
included substitutions for the residues P-263, P-264, S-265,
I-266, I-270, E-271, E-272, and P-263 and P-267 together (data
not shown).
The constitutive association of JAK-2 with the IFN-g recep-
tor b subunit requires the presence of the functionally impor-
tant b-chain residues. The functionally important sequences
detected within the IFN-g receptor b-chain intracellular do-
main displayed a strong resemblance to box 1 motifs, which are
thought to function in the intracellular domains of several
cytokine receptors as the sites of attachment for Janus family
kinases (19, 21, 31, 32). We therefore examined whether the
b chain interacted with the members of this enzyme family
that participate in IFN-g signaling by performing coprecipi-
tation experiments with L.hgR cells expressing either wild-
type b chains (L.hgR.mycb) or nonfunctional mutant b chains
(L.hgR.mycb263/7A and L.hgR.mycb270/4A). In these exper-
iments, cells were lysed in Brij-96 detergent-containing buffers,
the receptor b subunits were precipitated with the b-chain-
specific MAb 2HUB-159, and the precipitates were analyzed
by immunoblotting with anti-JAK-2. Wild-type b-chain precipi-
tates contained a 130-kDa band that reacted with JAK-2-spe-
cific antibodies, demonstrating that JAK-2 constitutively asso-
FIG. 2. The functionally important residues of the IFN-g receptor b-chain
intracellular domain reside within the membrane-proximal region. Wild-type b
chains, b chains lacking all but the first three cytoplasmic amino acids (bDIC),
b chains lacking 34 C-terminal residues (bD283-316), or b chains containing
substitutions at all three cytoplasmic tyrosines (Y-2523F, Y-2583L, and
Y-2733F) (b3DY) were stably transfected into L.hgR cells. Clonal cell lines
were assayed by flow cytometry for myc expression (a to d), and then the cells
were tested for IFN-g responsiveness by monitoring MHC class I expression
following treatment of the cells for 72 h with either human IFN-g (HuIFNg) (e
to h) or murine IFN-g (MuIFNg) (i to l).
FIG. 3. Identification of two functionally important sequences within the IFN-g
receptor b-chain intracellular domain. Human IFN-g receptor b chains contain-
ing alanine substitutions across blocks of four to seven contiguous amino acids with-
in the 32 membrane-proximal residues of the cytoplasmic domain were stably ex-
pressed in L.hgR cells, and clonal cell lines were tested for responsiveness to
human and murine IFN-g by flow cytometric analysis for MHC class I expression.
Mean channel shifts represent the difference in MHC class I fluorescence inten-
sity between untreated and IFN-g-stimulated (72 h) cells. L.hgR.mycb251/4A
represents a bulk-transfected population in which all cells express the human b
chain following fluorescence-activated cell sorter analysis for b-chain-expressing
cells. wt., wild type; HuIFNg, human IFN-g; MuIFNg, murine IFN-g.
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ciates with the wild-type b chain in unstimulated cells (Fig.
4A). In contrast, JAK-2 was not coprecipitated with either of
the two nonfunctional receptor b-chain intracellular-domain
mutants (Fig. 4A). Moreover, neither JAK-2 nor receptor a or
b subunits were present in immunoprecipitates generated with
a MAb specific for the murine p75 TNF receptor, a receptor
expressed on these cells that does not utilize the JAK-STAT
pathway for signaling (Fig. 4A). None of the b-chain precipi-
tates contained JAK-1 (data not shown). Thus, JAK-2 specif-
ically associates with the IFN-g receptor b-chain intracellular
domain in a constitutive manner, and association requires the
presence of the functionally important box 1-like b-chain se-
quences.
Ligand-dependent assembly of the IFN-g receptor subunits.
To determine whether the IFN-g receptor subunits interact
with one another in a constitutive or ligand-dependent man-
ner, L.hgR.mycb cells were treated with either PBS or human
IFN-g and lysed in Brij-96-containing buffers and a-chain im-
munoprecipitates were analyzed for the presence of the two
receptor polypeptides and JAK-2. In unstimulated cells, the
a-chain-specific MAb precipitated only the receptor a subunit.
These precipitates contained neither an anti-myc reactive com-
ponent nor JAK-2 (Fig. 5, lanes 1 and 9). In contrast, a-chain
precipitates from IFN-g-treated cells contained both a 60- to
65-kDa anti-myc reactive component and JAK-2 (Fig. 5, lanes
2 and 10). Neither protein was present in a-chain precipitates
generated from L.hgR cells that lacked the human b chain
(Fig. 5, lanes 3, 4, 11, and 12). To verify the identity of the 60-
to 65-kDa component detected by using the combination of
myc- and a-chain-specific MAbs, the experiment was repeated
with use of the b-chain-specific 2HUB-159 MAb to develop the
Western blots. The b chain was unequivocally detected in
a-chain precipitates derived from IFN-g-treated L.hgR.mycb
cells (Fig. 5, lane 6). These results thus demonstrate that the
IFN-g receptor a and b chains are not strongly preassociated
with one another on the surface of unstimulated cells but
rather are induced to associate in a ligand-dependent manner.
Definition of the role of the IFN-g receptor b chain in the
signaling process. Although our results indicated that the
b-chain intracellular domain was necessary for signaling, they
did not indicate whether the subunit’s ability to bind JAK-2
was sufficient for its function. To address this question, chi-
meric b-chain proteins in which the entire intracellular domain
of the protein was replaced either by full-length JAK-2 or by
c-src were generated (see Fig. 8). L.hgR cells stably expressing
these chimeric proteins were then examined for their ability to
activate the IFN-g signaling pathway by monitoring the capac-
ity of human IFN-g to effect both the tyrosine phosphorylation
of the human IFN-g receptor a chain and the activation of
Stat1. Human IFN-g induced the expected results in the con-
trol cell populations (L.hgR.mycb and L.hgR.mycbDIC) that
were included in these experiments. Specifically, the human
ligand induced receptor a-chain tyrosine phosphorylation and
Stat1 activation in L.hgR cells expressing wild-type b chain but
not in L.hgR cells expressing the truncated human b chain
(Fig. 6, lanes 2 and 4, and Fig. 7). Importantly, in L.hgR cells
expressing the b-chain–JAK-2 chimera, human IFN-g induced
the two events that are required for effecting IFN-g-dependent
cellular responses: receptor a-chain tyrosine phosphorylation
and activation of Stat1 DNA binding activity (Fig. 6, lane 6,
and Fig. 7). In the latter case, the presence of Stat1 in the
FIG. 4. JAK-2 constitutive association with the IFN-g receptor b chain re-
quires the presence of the functionally important b-chain sequences. L.hgR cells
(7.5 3 107) expressing either the full-length, myc-tagged b chain or b chains
containing alanine substitutions at residues 263 to 267 (mycb263/7A) or 270 to
274 (mycb270/4A) were lysed in Brij-96-containing buffers. JAK-2, the human b
chain (Hu b), and the murine p75 TNF receptor (TNFR2) were immunopre-
cipitated with polyclonal JAK-2 sera, MAb 2HUB-159, or MAb TR75-54.7,
respectively. Precipitates were subjected to SDS-PAGE on 7% polyacrylamide
gels under reducing conditions, and Western blot analysis using JAK-2-specific
antibodies was performed. The blots were stripped and reprobed with biotiny-
lated 2HUB-159. IP, immunoprecipitation.
FIG. 5. Ligand-induced assembly of the IFN-g receptor subunits. L.hgR or
L.hgR.mycb cells (7.5 3 107) were treated with either PBS or 10,000 IRU of
human IFN-g for 5 min at 378C and lysed in Brij-96-containing buffers. The
human IFN-g receptor a and b chains were immunoprecipitated with GIR-94
and 2HUB-159, respectively. Precipitates were subjected to SDS-PAGE on 7%
polyacrylamide gels under reducing conditions and analyzed by Western blotting
for the presence of the human receptor a chain, the myc-tagged human b chain,
and JAK-2. IP, immunoprecipitation.
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electrophoretic mobility shift assay complex was verified by
supershift analysis using Stat1-specific antiserum (data not
shown). In contrast, neither tyrosine phosphorylation of the
receptor a chain nor Stat1 activation was observed in human
IFN-g-treated L.hgR cells expressing the b-chain–src chimera
(Fig. 6, lane 8, and Fig. 7) despite the fact that these cells
expressed levels of the receptor a- and b-chain extracellular-
domain epitopes that were indistinguishable from those ex-
pressed on the human IFN-g-responsive cell types (Fig. 6,
bottom panel, and Fig. 8a to d).
A critical difference between the immunoprecipitation ex-
periments performed for Fig. 6 and those conducted for Fig. 5
is that the cells were lysed and the immunoprecipitations were
formed in the presence of Triton X-100 instead of Brij-96.
Triton X-100 is known to be a more stringent detergent than
Brij-96. Thus, under these more stringent conditions, the wild-
type human IFN-g receptor b subunit was not found in the
lysates of human IFN-g-treated cells (Fig. 6, lane 10). How-
ever, a tyrosine-phosphorylated form of the 170-kDa b-chain–
JAK-2 chimera was readily detected in a-chain immunopre-
cipitates derived from IFN-g-treated, chimera-expressing cells
(Fig. 6, lanes 6 and 14). This result demonstrates that the b-
chain–JAK-2 chimera indeed associates with the receptor a
chain in a ligand-dependent fashion. Moreover, it is of interest
that the chimera-containing ligand-assembled receptor com-
plex appears to be held together with an avidity higher than
that of the complex formed with wild-type receptor compo-
nents. This observation may indicate that the JAK-2 portion of
the chimera, which is covalently attached to the b-chain extra-
cellular domain, contributes to the overall avidity of the com-
plex through an as yet undefined interaction with cytoplasmic
portions of either the receptor a chain or its associated JAK-1.
Having established that the b chain–JAK-2 chimera could
participate in the IFN-g-mediated signaling process, we then
examined whether its functional activity was sufficient to sup-
port the induction of complete IFN-g-dependent biologic re-
sponses. For this purpose, two responses which depend upon
the ability of IFN-g to activate Stat1 were monitored (18).
Whereas enhancement of MHC class I expression is known
to be effected by IFN-g alone, induction of the iNOS gene
requires both IFN-g and a second signal, such as LPS, that
activates the NF-kB signaling pathway. As expected, L.hgR
cells expressing wild-type human receptor b chain responded
in both assays to human IFN-g (Fig. 8a, e, and m) while L.hgR
cells expressing the truncated human receptor b chain did not
(Fig. 8b, f, and n). Importantly, when expressed in L.hgR cells,
the b-chain–JAK-2 chimeric protein reconstituted a function-
ally active human IFN-g receptor that responded to human
IFN-g and effected enhancement of MHC class I expression
and induction of the iNOS gene (Fig. 8c, g, and o). In contrast,
the b-chain–src chimera, when expressed in L.hgR cells, was
unable to reconstitute either response to human IFN-g (Fig.
8d, h, and p). Western blot analysis confirmed the presence of
an intact b-chain–src chimera in the transfected cells, and in
vitro kinase assays demonstrated that this chimeric protein was
catalytically active (data not shown). These data rule out the
possibility that truncation or inactivation of the b chain-src
chimera accounted for its inability to participate in IFN-g
signaling. Taken together, the data demonstrate that the sole
obligate signaling function of the IFN-g receptor b-chain in-
tracellular domain is the capacity to interact with JAK-2 and
suggest that there may be at least some degree of substrate
specificity at the level of the kinases.
FIG. 6. Ligand-induced phosphorylation of the IFN-g receptor a chain in
L.hgR cells expressing the b-chain–JAK-2 chimera. Wild-type human b chain
(b), human b chain lacking all but the first three cytoplasmic amino acids (bDIC),
and human b-chain chimeras in which the b-chain intracellular domain was
replaced by murine JAK-2 (bJAK-2) or murine c-src (bsrc) were stably trans-
fected into L.hgR cells. L.hgR.mycbJAK-2 and L.hgR.mycbsrc represent bulk-
transfected populations in which all cells express the human receptor b-chain
chimera following fluorescence-activated cell sorter analysis for b-chain-express-
ing cells. L.hgR cells (1.8 3 107) were treated with either PBS or 10,000 IRU of
human IFN-g for 30 min at 378C. Cells were lysed in Triton X-100-containing
buffers, and a chains were immunoprecipitated with GIR-94. (Upper panel) The
precipitates from 1.5 3 107 cells were subjected to SDS-PAGE on 6% polyacryl-
amide gels and analyzed by Western blotting for the presence of tyrosine-
phosphorylated proteins using biotinylated 4G10 MAb. (Lower panel) Precipi-
tates from 33 106 cells were subjected to SDS-PAGE on 9% polyacrylamide gels
and analyzed by Western blotting using biotinylated forms of both GIR-94 and
2HUB-159. The 170-kDa tyrosine-phosphorylated species seen in lane 6 was
identified as the b-chain–JAK-2 chimera by Western blotting with 2HUB-159
(lane 14). IP, immunoprecipitation.
FIG. 7. Ligand-induced activation of Stat1 in L.hgR cells expressing the
b-chain–JAK-2 chimera. L.hgR cells (5 3 106) were stimulated with PBS (upper
panel) or with 1,000 IRU of either human IFN-g (HuIFNg; middle panel) or
murine IFN-g (MuIFNg; lower panel) per ml for 20 min at 378C. Nuclear
extracts were prepared, and 5 mg of each extract was incubated with a 32P-labeled
GRR oligonucleotide probe. Reaction mixtures were separated by electrophore-
sis through a 6% polyacrylamide gel and visualized by autoradiography.
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DISCUSSION
Herein, we define the essential role of the IFN-g receptor b
chain in IFN-g signaling. Specifically, we demonstrate that
JAK-2 constitutively associates with the receptor b chain under
physiologic conditions and identify the b-chain sequences
(P263PSIP267 and I270EEYL274) that are required for the in-
teraction. Moreover, we show that IFN-g induces the associa-
tion of the receptor a and b subunits, thereby promoting ac-
tivation of the Janus kinases that are specifically bound to each
receptor subunit. Finally, we show that a functionally active
human IFN-g receptor b chain can be generated by replacing
the entire b-chain intracellular domain with JAK-2 but not
with c-src. When expressed in L.hgR cells, the human b-chain–
JAK-2 chimera not only supported proximal IFN-g signaling
events in a ligand-dependent manner but also formed a func-
tionally active human IFN-g receptor system that, upon liga-
tion, was competent to mediate at least two complete IFN-g-
dependent cellular responses. These results demonstrate that
the sole obligate role of the IFN-g receptor b chain in the
signaling process is to recruit JAK-2 to the ligand-induced
receptor complex.
We and others have previously shown that all the pleiotropic
actions of IFN-g are manifest via the ability of the ligated
IFN-g receptor to activate Stat1 (5, 7, 11, 15, 18). The results
presented herein demonstrate that the participation of the b
chain in this process is dependent on its ability to chaperone
JAK-2 into the activated receptor complex. Therefore, this
capacity can be considered the minimal obligate function of
the b chain in the signaling process. At the present time, we
cannot rule out the possibility that, for certain complex IFN-
g-dependent responses, the intracellular domain of the b chain
may serve to recruit additional, as yet unidentified, signaling
proteins. However, our results clearly document that for re-
sponses such as MHC class I enhancement and iNOS induc-
tion, the JAK-2 binding function of the b-chain intracellular
domain is both necessary and sufficient to effect physiologic
levels of IFN-g responsiveness.
The functionally important sequences within the IFN-g re-
ceptor b-chain intracellular domain resemble box 1 motifs
present in the cytoplasmic domains of several other cytokine
receptors (19, 21, 31, 32). These motifs are characterized by
proline-rich sequences which have the general structure PXX-
PXP and are thought to mediate association of Janus kinases
with cytokine receptors (31, 32). Our results show that two
closely juxtaposed sequences, P263PSIP267 and I270EEYL274,
are critical for mediating JAK-2 attachment to the b chain.
Data obtained by using mutants which contained overlapping
alanine substitutions across the PPSIP sequence revealed that
no single proline residue was required for function but sug-
gested that at least one proline was necessary for function.
However, using an alanine substitution approach, we were
unable to identify any single residue within either of the two
b-chain intracellular-domain sequences that was critical for
function. We therefore conclude that the functionally critical
sequences identified in this study impart a structurally impor-
tant conformation to the b-chain intracellular domain, leading
to the generation of a binding site for JAK-2. This finding is in
contrast to results obtained with the human IFN-g receptor a
chain, wherein mutation of a single proline residue in the mem-
brane-proximal region of the a-chain intracellular domain ab-
rogated binding of JAK-1 to this receptor subunit and thereby
ablated the ability of the receptor a chain to transduce IFN-
g-dependent signals (15).
Particularly remarkable in the present study was our finding
that the b-chain–JAK-2 chimera could act as a subunit in the
generation of a functionally active IFN-g receptor in cells.
Even more surprising was the observation that the activity of
this chimera was regulated in a manner that was indistinguish-
able from that of the wild-type receptor b chain. Tyrosine phos-
phorylation of the IFN-g receptor a chain and Stat1 activation
FIG. 8. Reconstitution of human IFN-g responses in L.hgR cells by a human b-chain–JAK-2 chimera lacking the b-chain intracellular domain. L.hgR cells were
stably transfected with the four human b-chain constructs described in the legend to Fig. 6 and were assayed by flow cytometry for b-chain expression (a to d). These
cells were tested for IFN-g responsiveness by monitoring MHC class I expression following treatment of the cells for 72 h with either human IFN-g (HuIFNg) (e to
h) or murine IFN-g (MuIFNg) (i to l). These same cell lines were tested for induction of the iNOS gene following treatment with either LPS plus PBS (PBS), LPS
and human IFN-g (Hu IFNg), or LPS and murine IFN-g (Mu IFNg) (m to p).
VOL. 16, 1996 ROLE OF THE IFN-g RECEPTOR b CHAIN IN SIGNALING 3219
in L.hgR cells expressing this chimera (L.hgR.mycbJAK-2)
occurred only upon addition of ligand. Moreover, L.hgR.mycb
JAK-2 cells responded normally to human IFN-g. Perhaps
even more intriguing was the observation that the b-chain–src
chimera did not complement IFN-g signaling despite being
fully active as a tyrosine kinase as determined by in vitro kinase
assays. It is therefore possible that in this signaling system
tyrosine kinases display substrate specificity or are subject to
different regulatory cellular mechanisms. Additional work will
be necessary to clarify these issues.
The results presented herein also demonstrate that the IFN-
g receptor a and b chains are not preassociated at the cell
surface in unstimulated cells but rather are induced to assem-
ble in a ligand-dependent fashion. This observation is in agree-
ment with our previous study in which ligand-dependent a-sub-
unit–b-subunit interactions were demonstrated by chemical
cross-linking approaches (17). However, these results differ
from those of Sakatsume et al., who reported that the IFN-g
receptor a and b subunits could be coprecipitated together
from digitonin-solubilized, unstimulated cells (22). Experi-
ments conducted in our laboratories showed that IFN-g recep-
tor immunoprecipitates from digitonin lysates contained irrel-
evant membrane proteins, including the p75 TNF receptor.
This result suggests that the apparent interaction between the
IFN-g receptor subunits observed in digitonin lysates of un-
stimulated cells may be attributable to incomplete solubiliza-
tion of cellular membranes. In the present study we have used
the Brij-96 detergent, which fully solubilizes cell membranes
(as evidenced by the absence of p75 TNF receptor in IFN-g
receptor immunoprecipitates), and have established that the
receptor a and b subunits do not strongly interact with one
another in unstimulated cells. In contrast, the IFN-g receptor
a and b chains could be coprecipitated from Brij lysates of
IFN-g-treated cells, demonstrating that ligand induces recep-
tor subunit assembly. In addition, these lysates contained
JAK-2 and, as shown in our previous study, an activated form
of JAK-1 (15). These results demonstrate that IFN-g not only
effects receptor subunit interaction but also induces activation
of subunit-associated JAK-1 and JAK-2.
The results of this study further refine the current model of
IFN-g signaling (Fig. 9) (12). In unstimulated cells, the IFN-g
receptor a and b chains are not strongly associated with one
another but rather constitutively associate with inactive forms
of JAK-1 (15) and JAK-2 (16, 22; also the present study),
respectively. Addition of IFN-g, a homodimeric ligand, to re-
ceptor-bearing cells effects the rapid dimerization of the re-
ceptor a chain (10, 13). The formation of this complex leads to
the generation of a binding site for the receptor b chain (17;
also the present study), leading to the assembly of a receptor
complex that contains two receptor a subunits and one to two
receptor b subunits (17). Ligand-induced receptor a-chain–b-
chain oligomerization brings into juxtaposition the cytoplasmic
domains of the two receptor polypeptides and their associated
JAK kinases, thereby facilitating activation of JAK-1 and
JAK-2 (20, 33). The activated kinases then phosphorylate the
Y440 residue in the IFN-g receptor a-chain intracellular do-
main, thereby forming a paired set of receptor docking sites for
latent Stat1 (11, 12). Receptor-associated Stat1 is then tyrosine
phosphorylated, dimerizes, and translocates to the nucleus,
where it induces the transcription of IFN-g-inducible genes
(26–28). Thus, our results demonstrate that the role of the
IFN-g receptor b chain in the IFN-g signaling pathway is
limited to the pathway step in which JAK-1 and JAK-2 become
activated, which is a proximal event in the signal transduction
process.
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